Want to see BDTX full AI Analyst Report?
Top Page
Black Diamond Therapeutics
(NASDAQ:BDTX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▲(13.64% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily held back by weak and inconsistent financial performance (TTM zero revenue, losses, and cash burn) and soft technicals (below major moving averages with negative MACD). Corporate events add a meaningful offset due to positive Phase 2 clinical data, but valuation is also constrained by negative earnings (negative P/E) and no dividend support.
Positive Factors
Conservative balance sheet / low leverage
A low debt load (debt-to-equity ~0.14) gives a development-stage biotech meaningful financial flexibility. This reduces insolvency risk, supports funding for clinical programs or bridging financings, and improves the company's ability to pursue pivotal trials or partnerships over the medium term.
Negative Factors
TTM zero revenue and ongoing losses
No recurring revenue and sizeable TTM losses mean the company is not self-funding its operations. Persistent loss-making status increases reliance on external capital, raising dilution and execution risk that can delay trials or commercialization over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
A low debt load (debt-to-equity ~0.14) gives a development-stage biotech meaningful financial flexibility. This reduces insolvency risk, supports funding for clinical programs or bridging financings, and improves the company's ability to pursue pivotal trials or partnerships over the medium term.
Read all positive factors
Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$120.65M
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)2.40
Revenue Growth-100.00%
EPS Growth-392.92%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding57,453,747
10 Day Avg. Volume669,522
30 Day Avg. Volume1,679,202
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.33Price Target Upside487.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.63
Revenue Forecast (FY)$7.14M
Black Diamond Therapeutics Business Overview & Revenue Model
Company Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is ...
How the Company Makes Money
null...
Black Diamond Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 70.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | 69.67M | 0.00 | -437.00K | 0.00 | 0.00 |
| EBITDA | -40.88M | 22.69M | -69.33M | -82.00M | -90.66M | -125.39M |
| Net Income | -42.55M | 22.37M | -69.68M | -82.44M | -91.17M | -125.60M |
Balance Sheet | ||||||
| Total Assets | 125.03M | 143.01M | 122.64M | 158.57M | 156.25M | 247.68M |
| Cash, Cash Equivalents and Short-Term Investments | 110.51M | 128.65M | 98.58M | 131.40M | 122.81M | 209.79M |
| Total Debt | 16.97M | 18.78M | 22.19M | 25.30M | 28.14M | 28.46M |
| Total Liabilities | 28.94M | 30.80M | 39.35M | 41.83M | 40.56M | 51.78M |
| Stockholders Equity | 96.09M | 112.21M | 83.28M | 116.74M | 115.69M | 195.90M |
Cash Flow | ||||||
| Free Cash Flow | -32.01M | 29.61M | -62.30M | -66.75M | -85.27M | -102.86M |
| Operating Cash Flow | -32.01M | 29.61M | -62.30M | -66.72M | -85.08M | -100.15M |
| Investing Cash Flow | 22.08M | -44.91M | 16.97M | 16.35M | 53.37M | 130.61M |
| Financing Cash Flow | -30.00K | -146.00K | 25.55M | 71.93M | 177.00K | 729.00K |
Black Diamond Therapeutics Technical Analysis
Neutral
1.76
Price Trends
1.84
Positive
2.24
Negative
2.56
Negative
Market Momentum
0.03
Negative
65.47
Neutral
93.41
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Neutral. The current price of 1.76 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 1.84, and below the 200-day MA of 2.56, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 65.47 is Neutral, neither overbought nor oversold. The STOCH value of 93.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BDTX.
Black Diamond Therapeutics Risk Analysis
Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Black Diamond Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $120.65M | -2.73 | -38.80% | ― | -100.00% | -392.92% | |
45 Neutral | $146.15M | -1.81 | -116.86% | ― | -98.25% | 76.83% | |
44 Neutral | $50.52M | -0.85 | -108.72% | ― | 2.15% | 17.34% | |
43 Neutral | $98.31M | -3.19 | 5214.36% | ― | ― | 2.05% | |
43 Neutral | $46.01M | -0.15 | 73.11% | ― | 6.81% | 11.95% | |
43 Neutral | $156.45M | -1.58 | 65.27% | ― | 3.03% | 57.71% |
* Healthcare Sector Average
BDTX
Black Diamond Therapeutics
2.02
-0.77
-27.60%
KZIA
Kazia Therapeutics
13.21
4.94
59.73%
ONCY
Oncolytics Biotech
0.80
-0.14
-14.89%
KPTI
Karyopharm Therapeutics
1.99
-2.66
-57.20%
ADCT
ADC Therapeutics
1.05
-2.14
-67.08%
TCRX
TScan Therapeutics
0.77
-1.04
-57.35%
Black Diamond Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
Black Diamond Shareholders Approve Directors and Annual Say-on-Pay
Positive
Jun 29, 2026
On June 26, 2026, Black Diamond Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders in a virtual-only format, with 44,690,495 shares represented, establishing a quorum. Stockholders voted on director elections, auditor ratification, ex...
Business Operations and Strategy
Black Diamond Highlights Positive Phase 2 Silevertinib Lung Cancer Data
Positive
May 22, 2026
On May 21, 2026, Black Diamond Therapeutics reported positive Phase 2 data for silevertinib in treatment‑naïve non‑small cell lung cancer patients with non‑classical EGFR mutations, based on an April 11, 2026 data cutoff. In...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.